Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mas Rina Wati Haji Abdul Hamid has a total of 113 co-authors. Here are the top co-authors by number of shared publications:

  • Aklimah Mustapa

    Halalan Thayyiban Research Centre, Universiti Islam Sultan Sharif Ali, Jalan Tutong, Sinaut, Negara Brunei Darussalam

    3 shared publications
  • Siti Nur Idayu Matusin

    Halalan Thayyiban Research Centre, Universiti Islam Sultan Sharif Ali, Jalan Tutong, Sinaut, Negara Brunei Darussalam

    3 shared publications
  • Siti Nur Idayu Matusin

    Faculty of Halal Science and Sustainable Tourism, Universiti Islam Sultan Sharif Ali, Sinaut Campus, KM33, Jalan Tutong, Kampung Sinaut, Tutong TB1741, Brunei

    3 shared publications
  • Zen Huat Lu

    Affiliation Pengiran Anak Puteri Rashidah Sa’adatul Bolkiah (PAPRSB) Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Negara Brunei Darussalam

    3 shared publications
  • Fatin Nurizzati Mohd Jaya

    Affiliation Pengiran Anak Puteri Rashidah Sa’adatul Bolkiah (PAPRSB) Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Negara Brunei Darussalam

    2 shared publications
  • Hazirah Zainal Abidin

    Affiliation Pengiran Anak Puteri Rashidah Sa’adatul Bolkiah (PAPRSB) Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Negara Brunei Darussalam

    2 shared publications

Latest Publications

  • Open Access

    Mitochondrial dysfunction and ROS signaling drive metabolic adaptation and plasticity in cancer

    by Izzah Bungsu, Mark I. R. Petalcorin, Mas Rina Wati Haji Abdul Hamid

    Mitochondrial dysfunction and reactive oxygen species (ROS) are increasingly recognized as key drivers of cancer metabolism, redox homeostasis, and cellular adaptation. Beyond their classical roles in energy production and oxidative balance, mitochondria function as central regulators of metabolic signaling influencing tumour growth, survival, and therapeutic response. Although mitochondrial dysfunction, redox imbalance, and metabolic adaptation have been extensively investigated, these interconnected processes are often examined independently, limiting a comprehensive understanding of their collective contribution to tumour progression. Emerging evidence demonstrates that mitochondrial dysfunction and ROS promote metabolic adaptation and plasticity, partly through epigenetic reprogramming, enabling cancer cells to survive and proliferate under conditions of energetic, environmental, and therapeutic stress. This review synthesizes current evidence linking mitochondrial dysfunction, ROS signaling, and metabolic adaptation, with particular emphasis on the molecular mechanisms underlying these interactions and their role in therapy resistance. It also discusses emerging therapeutic strategies targeting oxidative phosphorylation (OXPHOS), redox homeostasis, and metabolic adaptation, while highlighting the challenges posed by metabolic plasticity, tumour heterogeneity, and treatment-associated toxicities. Collectively, the evidence supports integrated therapeutic approaches that combine mitochondrial and metabolic targeting with biomarker-guided patient stratification to improve the durability and precision of cancer treatment.

  • Open Access

    Prevalence and spectrum of germline BRCA1 and BRCA2 mutations in multiethnic cohort of breast cancer patients in Brunei Darussalam

    by Siti Nur Idayu Matusin, Nuramalina Mumin, Hazirah Zainal Abidin, Fatin Nurizzati Mohd Jaya, Zen Huat Lu, Mas Rina Wati Haji Abdul Hamid

    This is the first genetic study of its kind in Brunei Darussalam. BRCA1 and BRCA2 genes are the most well-known and well described predictors of hereditary breast cancer due to their clinical importance. This study aimed to identify the prevalence and mutation spectrum of the BRCA1 and BRCA2 germline mutations among 120 unselected series of Brunei breast cancer patients. We screened the entire coding region of BRCA1 and BRCA2 gene using Sanger sequencing and next-generation sequencing methods and identified three pathogenic and one likely pathogenic mutations in the BRCA2 gene. Of the 120 patients, 6 (5%) were BRCA2 carriers which confirm that BRCA2 carriers are more common in the Asian population compared to the Caucasian population. One BRCA2 mutation observed only in the Chinese ethnicity of the Brunei breast cancer population suggest a probability of the mutation being a founder effect in the Southern Chinese population. Brunei BRCA2 carriers were more likely to have a positive family history of breast and/or ovarian cancers and have more than one family members in the first-degree relatives diagnosed with breast cancer.

  • Open Access

    Accelerating access to human genomics for public health: perspectives from the Western Pacific region

    by Kidong Park, Mengji Chen, Greco Mark Malijan, Dayoung Song, Anna Laura Ross, Elena Ambrosino, Catalina Lopez-Correa, Syahril Abdullah, Pio Justin Asuncion, Tiffany Boughtwood, et al.


  • Open Access

    Prevalence and spectrum of germline BRCA1 and BRCA2 mutations in multiethnic cohort of breast cancer patients in Brunei Darussalam

    by Siti Nur Idayu Matusin, Nuramalina Mumin, Hazirah Zainal Abidin, Fatin Nurizzati Mohd Jaya, Zen Huat Lu, Mas Rina Wati Haji Abdul Hamid

    This is the first genetic study of its kind in Brunei Darussalam. BRCA1 and BRCA2 genes are the most well-known and well described predictors of hereditary breast cancer due to their clinical importance. This study aimed to identify the prevalence and mutation spectrum of the BRCA1 and BRCA2 germline mutations among 120 unselected series of Brunei breast cancer patients. We screened the entire coding region of BRCA1 and BRCA2 gene using Sanger sequencing and next-generation sequencing methods, and identified three pathogenic and one likely pathogenic mutations in the BRCA2 gene. Of the 120 patients, 6 (5%) were BRCA2 carriers which confirm that BRCA2 carriers are more common in the Asian population compared to the Caucasian population. One BRCA2 mutation observed only in the Chinese ethnicity of the Brunei breast cancer population contributes to the probability of the mutation being a founder effect in the Southern Chinese population. Brunei BRCA2 carriers were more likely to have a positive family history of breast and/or ovarian cancers and have more than one family members in the first-degree relatives diagnosed with breast cancer.

  • Open Access

    Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis

    by Nurul Wafiqah Saipol Bahrin, Siti Nur Idayu Matusin, Aklimah Mustapa, Lu Zen Huat, Sriyani Perera, Mas Rina Wati Haji Abdul Hamid

    Background: Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtype classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients. Methods: A systematic search was conducted in MEDLINE (PubMed), Science Direct, Scopus, and Cochrane Library databases. Studies were selected if they included Asian breast cancer patients treated with neoadjuvant chemotherapy and contained data for qualitative or quantitative analyses. The quality of the included studies was assessed using the Newcastle Ottawa Scale. Following the random effects model, pooled odds ratios or hazard ratios with 95% confidence intervals for pCR were analysed using Review Manager Software. Heterogeneity between studies was assessed using Cochran’s Q-test and I2 test statistics. Results: In total, 19,708 Asian breast cancer patients were pooled from 101 studies. In the neoadjuvant setting, taxane-anthracycline (TA) chemotherapy showed better pCR outcomes in triple-negative breast cancer (TNBC) (ppppPIK3CA were significantly associated with better pCR outcomes when treated with TA in the neoadjuvant setting (p=0.001). Conclusions: In the neoadjuvant setting, molecular subtypes (HER2E and TNBC), biomarkers (ER, PR, HER2, HR, Ki-67, nm23-H1, CK5/6, and Tau), and gene (PIK3CA) are associated with increased pCR rates in Asian breast cancer patients. Hence, they could be further explored for their possible role in first-line treatment response, which can be utilised to treat breast cancer more efficiently in the Asian population. However, it needs to be further validated with additional powered studies. Systematic review registration: PROSPERO CRD42021246295.


  • Open Access

    Low prevalence of germline TP53 and PALB2 mutations in unselected cohort of breast cancer patients from Brunei Darussalam

    by Siti Nur Idayu Matusin, Zen Huat Lu, Mas Rina Wati Haji Abdul Hamid

    Background: Breast cancer is the most frequent malignancy affecting women worldwide. The majority of breast cancer occurs sporadically, with only 5-10% being caused by inheritance of susceptibility genes. In Brunei Darussalam, breast cancer is the leading cause of cancer in women. The prevalence and clinical relevance of breast cancer susceptibility genes in Brunei breast cancer patients is unknown. We investigated the prevalence and clinical relevance of germline TP53 and PALB2 genes, recognised to confer a high and moderate risk respectively, in the development of breast cancer in an unselected cohort of Brunei breast cancer patients. Methods: Genomic DNA was extracted from peripheral blood samples of 54 unselected Brunei breast cancer patients. The DNA samples were sequenced for germline BRCA1, BRCA2, TP53, and PALB2 variants using targeted panel sequencing on a Hi-Plex NGS platform. Identified variants were analysed for their pathogenicity classification based on clinical/population/mutation databases, in-silico data, and available functional data analysis. Chi-square test was used to determine the association between TP53 codon 72 and response to chemotherapy in Brunei breast cancer patients. Results: We identified two TP53 and five PALB2 missense variants in our study population. Five of the identified variants were classified as variants of uncertain significance (one in TP53 and four in PALB2) giving a prevalence of TP53 and PALB2 variant of uncertain significance carriers at 1.9% and 9.3%, respectively. No pathogenic TP53 and PALB2 mutation was identified in this study suggesting the rarity of these genes in breast cancer.TP53 codon 72 had no association with Brunei breast cancer patients’ response to chemotherapy supporting the benign characteristic of the variant P72R. Conclusions: Our current findings suggest that the contribution of germline TP53 and PALB2 genes in unselected Brunei breast cancer patients is rare, and a larger number of participants will be required to confirm this finding.

  • Open Access

    Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: A systematic review and meta-analysis

    by Mas Rina Wati Haji Abdul Hamid, Nurul Wafiqah Saipol Bahrin, Siti Nur Idayu Matusin, Aklimah Mustapa, Lu Zen Huat, Sriyani Parera

    Background Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtypes classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients. Methods A systematic search was conducted in MEDLINE (PubMed), Science Direct, Scopus, and Cochrane Library databases. Studies were selected if they included Asian breast cancer patients treated with neoadjuvant chemotherapy and contained data for qualitative or quantitative analyses. The quality of the included studies was assessed using the Newcastle Ottawa Scale. Following the random effects model, pooled odds ratios or hazard ratios with 95% confidence intervals for pCR were analysed using Review Manager Software. Heterogeneity between studies was assessed using Cochran’s Q-test and I2 test statistics. Results 19,708 Asian breast cancer patients were pooled from 101 studies. In the neoadjuvant setting, taxane-anthracycline (TA) chemotherapy showed better pCR outcomes in triple negative breast cancer (TNBC) (p < 0.0001) and human epidermal growth factor receptor 2 enriched (HER2E) (p < 0.0001) than luminal breast cancer patients. Similarly, taxane-platinum (TP) chemotherapy also showed better pCR outcomes in TNBC (p < 0.0001) and HER2E (p < 0.0001). Oestrogen receptor (ER)-negative, progesterone receptor (PR)-negative, HER2-positive and high Ki-67 were significantly associated with better pCR outcomes when treated with either TA or TP. Asian breast cancer patients harbouring wildtype PIK3CA were significantly associated with better pCR outcomes when treated with TA in the neoadjuvant setting (p = 0.001). Conclusions In the neoadjuvant setting, molecular subtypes (HER2E and TNBC), biomarkers (ER, PR, HER2, HR, Ki-67, nm23-H1, CK5/6, and Tau), and gene (PIK3CA) are associated with increased pCR rates in Asian breast cancer patients. Hence, they could be further explored for their possible role in first-line treatment response, which can be utilised to treat breast cancer more efficiently in the Asian population. However, it needs to be further validated with additional powered studies. Systematic review registration: PROSPERO CRD42021246295

  • Open Access

    Public knowledge of and attitudes toward genetics and genetic testing in Brunei Darussalam

    by Hazreana Jaya, Siti Nur Idayu Matusin, Aklimah Mustapa, Muhammad Syafiq Abdullah, Mas Rina Wati Haji Abdul Hamid

    The world has been experiencing encouraging research in genetics, but current public knowledge, awareness, and perception of this area remain unknown for Brunei Darussalam. This study aimed to investigate the Brunei population’s genetics and genetic testing literacy, and their attitude toward them. A cross-sectional study was carried out targeting public population in Brunei Darussalam. Questionnaires on knowledge and attitudes were randomly distributed in frequented venues in the Brunei–Muara district and uploaded online for distribution through social media. Responses were scored and analyzed using appropriate statistical methods. Overall, the sample population (n = 474) comprised 75.7% female, 64.3% aged 18–29 years old, 39.7% with a bachelor’s degree, and 2.3% and 5.3% with a personal history and family history of genetic disease(s), respectively. Younger participants scored higher for disease-related questions and showed more concern on the impact of testing on employment but were more fearful of testing. Higher educational qualifications were associated with a higher knowledge score, a more optimistic view on DNA research, and less reluctance to take a genetic test for an untreatable disease. Participants with a personal history of genetic disease(s) were more knowledgeable and displayed higher curiosity. Participants with a family history of genetic disease(s) were also more knowledgeable and would want testing even for an untreatable disease. Significantly less was known about the social consequences of testing compared to the medical possibilities. Investigating the knowledge and attitudes of the population is vital preceding efforts toward national adaptation of genetic testing, keeping in mind the various obstacles and issues surrounding the subject.


  • Open Access

    Cholecalciferol improves cognitive impairment by amending impaired insulin signaling in sporadic Alzheimer’s Disease Rats

    by Tushar Kanti Das, Estinnorell Yong, Mas R.W. Abdul Hamid

    Alzheimer’s disease (AD) is the most common form of dementia and contributes to 50-70% of neurodegenerative brain diseases. AD has been associated with poor vitamin D nutrition, which is correlated with low mood and impaired cognitive performance in older people. The impact of vitamin D on the insulin signaling pathway in AD is not well known. Hence, this study was to explore the effects of cholecalciferol (Vitamin D 3 ) on the expression of IRS-1, IRS-2, Akt, pAkt (Ser473), and GLUT3 in the sporadic AD rat model. The rats were induced to develop sporadic AD by intraperitoneal administration of Scopolamine. The downregulation expression of IRS-1, IRS-2, Akt, pAkt (Ser473) and GLUT3 may lead to impaired insulin signaling which is associated with the development of AD. All these data were compared to Saline-treated control rats. However, cholecalciferol treatment in AD rats may improve memory performance by increasing the expression of insulin signaling proteins and hence ameliorates impaired insulin signaling. All these data were compared to Scopolamine–induced AD rats and sunflower oil-treated rats. Therefore, cholecalciferol treatment may be an alternative approach for the treatment of AD.

  • Open Access

    Applications of next generation sequencing in the screening and diagnosis of thalassemia: A mini-review

    by Syahirah Amnani Suhaimi, Ihsan Nazurah Zulkipli, Hazim Ghani, Mas Rina Wati Abdul-Hamid

    Thalassemias are a group of inherited blood disorders that affects 5–7% of the world population. Comprehensive screening strategies are essential for the management and prevention of this disorder. Today, many clinical and research laboratories have widely utilized next-generation sequencing (NGS) technologies to identify diseases, from germline and somatic disorders to infectious diseases. Yet, NGS application in thalassemia is limited and has just recently surfaced due to current demands in seeking alternative DNA screening tools that are more efficient, versatile, and cost-effective. This review aims to understand the several aspects of NGS technology, including its most current and expanding uses, advantages, and limitations, along with the issues and solutions related to its integration into routine screening and diagnosis of thalassemias. Hitherto, NGS has been a groundbreaking technology that offers tremendous improvements as a diagnostic tool for thalassemia in terms of its higher throughput, accuracy, and adaptability. The superiority of NGS in detecting rare variants, solving complex hematological problems, and providing non-invasive alternatives to neonatal diagnosis cannot be overlooked. However, several pitfalls still preclude its use as a stand-alone technique over conventional methods.